EnsoData, Inc.
$85.1K 14 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Dutch Ophthalmic, USA
Dutch Ophthalmic, USA reported $85,026.86 across General Payments, Research, and Ownership to 371 physicians and teaching hospitals across 371 transactions.
- $85.0K Below-median payer
- All-tracks total
- 371 Above-median volume
- Transactions
- 371 Above-median reach
- Recipients
- −$89.4K
- General Payments vs PY2023
Dutch Ophthalmic, USA reported $85,026.86 across all CMS Open Payments tracks (General + Research + Ownership) to 371 physicians and teaching hospitals in Program Year 2024 - ranking #1226 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $85,026.86, averaging $229.18 per recipient.
Dutch Ophthalmic, USA's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
22/100
Total payments
F
11/100
Transaction volume
F
13/100
Physician reach
F
13/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer dutch-ophthalmic-usa Dutch Ophthalmic, USA
$85.0K · #1226/1,925 · 0.0% industry · PY2024
- TOT $85.0K
- RANK #1226
- SHARE 0.0%
- TXN 371
- RCP 371
- CAT 4
- GEN $85.0K
- ΔGEN −$89.4K
- TOP1 12.1%
- PY 2024
Volume peers
Nearest volume peer: EnsoData, Inc. ($85.1K)
Dutch Ophthalmic, USA sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Dutch Ophthalmic, USA's CMS-reported General Payments decreased by $89.4K (−51.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: DUTCH OPHTHALMIC, USAPY2023: DUTCH OPHTHALMIC, USAPY2024: Dutch Ophthalmic, USA. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $174,381.10
- PY2024
- $85,026.86
What the Data Shows for Dutch Ophthalmic, USA
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Dutch Ophthalmic, USA that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 4 general-payment categories charted below, "Travel and Lodging" is the largest at $39.2K across 42 transactions, 46.1% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Dutch Ophthalmic, USA made 4 types of general payments. "Travel and Lodging" is the largest category at $39.2K, 46.1% of General Payments.
Dutch Ophthalmic, USA reports 4 general-payment categories - the top three are Travel and Lodging (46.1%), Food and Beverage (32.6%), and Consulting Fee (20.7%). The remaining 1 category make up 0.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Dutch Ophthalmic, USA divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $39.2K | 42 | 46.1% |
| Food and Beverage | $27.7K | 323 | 32.6% |
| Consulting Fee | $17.6K | 5 | 20.7% |
| Education | $477.00 | 1 | 0.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $30,004.06 (35.3%) of $85,026.86 in this company's General Payments records across 261 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Dutch Ophthalmic, USA
The five named recipients with the highest reported General Payments from this company
- 1
Asheesh Tewari
$10,292.51 across 3 reported transactions
- 2
Courtney M Crawford
$6,104.38 across 9 reported transactions
- 3
Dilraj S Grewal
$5,832.58 across 2 reported transactions
- 4
Christopher D Riemann
$4,080.93 across 4 reported transactions
- 5
Gaurav K Shah
$3,693.66 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Dutch Ophthalmic, USA's spend rank (#1226 of 1,925, bottom 36% by spend) and concentration rank (#1,428 of 1,838, bottom 22% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Carl Zeiss Meditec USA, Inc. : $719.3K total payments, HHI 348
- Checkpoint Surgical, Inc : $293.7K total payments, HHI 348
- Medline Industries LP : $1.9M total payments, HHI 347
- Olympus Corporation : $904.0K total payments, HHI 343
- Coherus Biosciences Inc. : $361.8K total payments, HHI 343
- Orphalan Inc : $61.9K total payments, HHI 342
- Dutch Ophthalmic, USA (this company) : $85.0K total payments, HHI 342
- BonaliveInc : $3.3K total payments, HHI 342
- Davol Inc. : $4.4M total payments, HHI 337
- Eli Lilly Export S.A. Puerto Rico Branch : $47.2K total payments, HHI 334
- Profound Medical Corp. : $125.2K total payments, HHI 329
- Argenx US, Inc. : $3.5M total payments, HHI 327
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Dutch Ophthalmic, USA's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Dutch Ophthalmic, USA.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Dutch Ophthalmic, USA.
Showing 6 of 1,924 companies with CMS-reported payment data.
Samsung Bioepis Co., Ltd.
$85.2K 55 recipients
Compare payment profiles
Gemini Mountain Medical, LLC
$85.4K 577 recipients
Compare payment profiles
Pramand LLC
$84.3K 67 recipients
Compare payment profiles
Richard Wolf Medical Instruments Corp.
$85.7K 28 recipients
Compare payment profiles
Collagen Matrix, Inc
$83.9K 32 recipients
Compare payment profiles
Put this to use
Dutch Ophthalmic, USA ranks #1226 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just Dutch Ophthalmic, USA. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.